Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,696.60GBp
20 Nov 2019
Change (% chg)

-19.80 (-1.15%)
Prev Close
1,716.40
Open
1,718.00
Day's High
1,729.80
Day's Low
1,696.60
Volume
6,208,253
Avg. Vol
6,825,045
52-wk High
1,796.40
52-wk Low
1,408.80

Select another date:

Fri, Nov 15 2019

Photo

GSK sees breakthrough in shingles vaccine output in 2024

WAVRE, Belgium GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.

UPDATE 1-GSK sees breakthrough in shingles vaccine output in 2024

* China market for now a distant opportunity (Adds role of vaccines for GSK, details on China launch)

GSK eyes 'step change' in shingles vaccine output in 2024

WAVRE, Belgium, Nov 15 GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production.

UPDATE 2-Merck KGaA raises 2019 guidance after Versum takeover

* Pharmaceuticals/lab supplies units plus FX effects boost result

GSK raises profit forecast after shingles vaccine sales boost

GlaxoSmithKline on Wednesday raised its annual profit forecast for the second time this year as sales of its shingles vaccine beat expectations and older medicines, including HIV treatments, continued to sell well.

UPDATE 2-GSK raises profit forecast after shingles vaccine sales boost

* Shares hit more than six-year high (Adds CEO comments, shares)

GSK lifts annual profit forecast after Q3 beat

Oct 30 GlaxoSmithKline Plc on Wednesday raised its annual profit forecast for the second time this year as soaring sales of its Shingles vaccine helped offset a hit from generic competition to its blockbuster asthma drug Advair.

GlaxoSmithKline starts late-stage trial for experimental antibiotic

GlaxoSmithKline Plc said on Monday it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infections and gonorrhoea, a type of sexually transmitted infection.

UPDATE 1-GlaxoSmithKline starts late-stage trial for experimental antibiotic

Oct 28 GlaxoSmithKline Plc said on Monday it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infections and gonorrhoea, a type of sexually transmitted infection.

GSK gets FDA nod for wider use of ovarian cancer drug Zejula

GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

Select another date: